Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)

SueWallSt.com

A $4.3 million to $6.3 million gap between Integra's preliminary third-quarter revenue and the Wall Street estimate sent IART shares lower. SueWallSt notifies investors of a pending investigation into potential securities claims for shareholders who lost money.

NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Integra LifeSciences (NASDAQ: IART) shares fell sharply on October 2, 2026, after the Company put preliminary third-quarter revenue at $410 million to $412 million -- short of the $416.3 million FactSet consensus estimate. Investors who bought IART and are now holding losses may have legal rights. Affected shareholders are encouraged to submit their IART loss details now or contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

Recommended for you